Published within
|«
«
|
...
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017. Eight more marketed brands are set to achieve blockbuster status over the 10-year forecast period, driven by the persistent unmet need that still exists across a number of tumor types.
Published By Datamonitor
|
03 Oct 2008 |
|
Expert View
|
Cytotoxic therapy has been the cornerstone of cancer treatment for many years: indeed, despite a number of unpleasant side effects, the therapy is relatively effective. However, because of this maturity in the market, generics companies remain keen to emulate the success of several cytotoxic brands that have attained blockbuster sales over the years.
Published By Datamonitor
|
28 Nov 2008 |
|
CommentWire
|
The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.
Published By Datamonitor
|
09 Jan 2009 |
|
CommentWire
|
Sales of Tamiflu, Roche's influenza treatment, have plummeted by 68% compared to 2007, reflecting the waning attention paid to pandemic preparation by governments worldwide and the emerging competition from Relenza and pandemic influenza vaccines. Despite insufficient stockpiles in most countries, Datamonitor believes that the seasonal market will continue to gain importance for Tamiflu's sales.
Published By Datamonitor
|
05 Feb 2009 |
|
CommentWire
|
GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK lost its position as market leader to Gilead in 2007. The new collaboration with Idenix will, however, help the company to maintain its share in the fiercely competitive HIV market.
Published By Datamonitor
|
09 Feb 2009 |
|
CommentWire
|
Having signed an agreement to jointly develop Unit Dose Budesonide, Map Pharmaceuticals' novel formulation of nebulized budesonide, AstraZeneca had hoped to negate a key competitive threat while adding to its own portfolio. However, recent study results suggest that AstraZeneca's strategy may have been in vain, while the consequences may be more far reaching for MAP.
Published By Datamonitor
|
25 Feb 2009 |
|
CommentWire
|
Following an analysis by independent safety monitors, Synta Pharmaceuticals has been forced to halt a pivotal Phase III trial of elesclomol in advanced melanoma. While this news is particularly disappointing for the melanoma market, where a significant unmet need exists, the setback also presents ominous consequences for Synta.
Published By Datamonitor
|
02 Mar 2009 |
|
CommentWire
|
Having previously been withdrawn due to purity concerns, Indevus Pharmaceuticals' Valstar has received FDA approval for reintroduction into the bladder cancer market. The drug should be able to reclaim its original market share, although this will require an effective marketing strategy. Indevus must ensure that Valstar can withstand potential competitive pressure in the future.
Published By Datamonitor
|
02 Mar 2009 |
|
Expert View
|
As a standalone company, Merck & Co. faces a tough future of declining sales. Datamonitor forecasts that the merger with Schering-Plough will succeed in returning Merck to positive sales growth and provide a raft of new pipeline and marketed products. However, before this can be achieved, outstanding issues surrounding Schering-Plough's partnership with Johnson & Johnson must be resolved.
Published By Datamonitor
|
13 Mar 2009 |
|
CommentWire
|
Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.
Published By Datamonitor
|
13 Mar 2009 |
|
|«
«
|
...
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.